Cagrilintide/Semaglutide

卡瑞林肽/司美格鲁肽

Report date: 2026/05/21 20:00:22

Base Information

Drug NameCagrilintide/Semaglutide
Drug Alias NameCagriSema卡格列肽/司美格鲁肽NN9388
ClassificationBiologics
Mechanisms of ActionAmylin receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsAmylin ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetic peripheral neuropathyOverweightBody Weight +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsYes CagrilintideSemaglutide
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovo Nordisk A/SNovo Nordisk (China)Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/SNovo Nordisk (China)Pharmaceuticals Co LtdNovo Nordisk Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsDiabetic peripheral neuropathyOverweightBody Weight +[5] 
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A